Also known as pnc27
PNC-27 is a synthetic 32-amino-acid chimeric anticancer research peptide that fuses a p53 MDM-2/HDM-2-binding sequence (residues 12-26) with a membrane-residency leader peptide. In preclinical cell-culture and rodent xenograft models, it has been reported to selectively bind HDM-2 aberrantly displayed on the plasma membrane of many cancer cells, form transmembrane pores, and cause rapid colloid-osmotic necrosis while sparing normal cells that lack surface HDM-2 (Sarafraz-Yazdi et al., 2010). All published evidence is preclinical: there are no registered human clinical trials. Vendor sale to consumers seeking cancer treatment is a serious safety and regulatory concern.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
PNC-27 combines the p53 transactivation-domain residues 12-26 (HDM-2/MDM-2-binding motif) with a membrane-penetrating leader sequence. In cancer cells that aberrantly display HDM-2 on the outer plasma membrane, PNC-27 docks onto membrane HDM-2 and assembles into transmembrane pores, triggering loss of ionic gradients and colloid-osmotic necrosis rather than classical caspase-mediated apoptosis (Sarafraz-Yazdi et al.
Pharmacokinetic properties
Half-life
Not characterized in humans; preclinical IV/IP studies suggest minutes-to-hours plasma residence
Routes
intravenous · intraperitoneal · subcutaneous
Bioavailability
Not orally bioavailable. Original preclinical work used IV and IP administration. Subcutaneous self-administration is unsupported by data.
Amino-acid sequence
MPRFMDYWEGLNQRSRKRALSR
Use & research dosing
No human clinical dose has ever been established for PNC-27. Preclinical murine xenograft studies have used roughly 10-30 mg/kg/day intraperitoneally or intravenously for short courses (Sarafraz-Yazdi et al., 2010). Gray-market self-experimentation reports of subcutaneous injection exist online but are not supported by any safety, pharmacokinetic, or dose-finding evidence in humans. Allometric scaling from rodent IP dosing to a human SC protocol is not validated. There is no FDA-approved label, no Investigational New Drug filing publicly registered, and no validated formulation.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
PNC-27 was originated by Pincus, Michl and colleagues at NYMC and remains a preclinical experimental anticancer peptide despite roughly two decades of work. There is no IND-stage or registered clinical trial. The serious red flag is vendor sale of PNC-27 to retail buyers, some of whom self-administer it as DIY oncology in lieu of standard care. Any cancer-treatment claim attached to a research-chemical sale is a regulatory and patient-safety violation. Knowledge-base copy should consistently flag this.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.